NEUROCRINE REVEALS RESULTS OF TRIAL FOR MULTIPLE SCLEROSIS

Neurocrine Biosciences has reported that results of its Phase II clinical trial using its altered peptide ligand technology for multiple sclerosis did not meet its primary endpoint and demonstrate efficacy although the product was safe and well-tolerated.

The company said that it has discontinued the development of its APL-MS program. The Company will complete its other APL Phase II study, which is evaluating the APL technology for the treatment of Type 1 diabetes, utilizing a different APL epitope.